Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocaratuzumab

Drug Profile

Ocaratuzumab

Alternative Names: AME-133; AME-133v; LY 2469298

Latest Information Update: 05 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Applied Molecular Evolution
  • Developer Applied Molecular Evolution; MENTRIK Biotech
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Follicular lymphoma; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 04 Feb 2016 No development reported - Phase-I for Rheumatoid arthritis in USA (IV)
  • 04 Feb 2016 No development reported - Phase-II for Follicular lymphoma in Japan (IV)
  • 04 Feb 2016 No development reported - Phase-II for Non-Hodgkin's lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top